LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 ...

Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

These three stocks could potentially help investors create a stable – and growing – stream of passive income in the years ...

Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

The new threat has Eli Lilly investors running scared, but Wall Street analysts insist Eli Lilly stock is still a buy. GLP-1 drug prices are falling. That's good news for patients, but perhaps not ...